Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma because Celgene did not provide an evidence submission.
NICE will review this decision if Celgene decides to make a submission.
